Last reviewed · How we verify
Lumiracoxib (drug)
Lumiracoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce inflammation and pain.
Lumiracoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce inflammation and pain. Used for Osteoarthritis, Rheumatoid arthritis, Acute pain.
At a glance
| Generic name | Lumiracoxib (drug) |
|---|---|
| Sponsor | Novartis |
| Drug class | Selective COX-2 inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | Phase 3 |
Mechanism of action
As a selective COX-2 inhibitor, lumiracoxib blocks the COX-2 enzyme, which is responsible for producing prostaglandins that mediate inflammation, pain, and fever. By selectively targeting COX-2 over COX-1, the drug aims to provide anti-inflammatory and analgesic effects while potentially reducing gastrointestinal toxicity associated with non-selective NSAIDs.
Approved indications
- Osteoarthritis
- Rheumatoid arthritis
- Acute pain
Common side effects
- Gastrointestinal disorders
- Cardiovascular events
- Hepatotoxicity
- Headache
Key clinical trials
- Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib (PHASE4)
- Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension (PHASE4)
- Safety Study of Renal Function in Patients With Chronic Kidney Failure Taking Lumiracoxib or Diclofenac for Arthralgia (PHASE2)
- Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis (PHASE3)
- 52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine (PHASE3)
- Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA) (PHASE3)
- Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA) (PHASE3)
- Efficacy and Safety of Lumiracoxib (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lumiracoxib (drug) CI brief — competitive landscape report
- Lumiracoxib (drug) updates RSS · CI watch RSS
- Novartis portfolio CI